Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures

BMC Medical Genomics

Volumn 4, Issue , 2011, Pages

  Fan, Cheng ^a   Prat, Aleix ^a,b   Parker, Joel S ^a,b   Liu, Yufeng ^a,c   Carey, Lisa A ^b   Troester, Melissa A ^d   Perou, Charles M ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d The University of North Carolina at Chapel Hill   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; COPY NUMBER VARIATION; DISEASE FREE SURVIVAL; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; ADJUVANT THERAPY; BIOLOGICAL MODEL; BREAST TUMOR; COMPARATIVE STUDY; EVALUATION; FEMALE; FORECASTING; GENE EXPRESSION; GENETICS; METHODOLOGY; PROPORTIONAL HAZARDS MODEL;

BREAST NEOPLASMS; FEMALE; FORECASTING; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MODELS, BIOLOGICAL; NEOADJUVANT THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 78650958088     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-4-3     Document Type: Article

References (75)

1. Sorting out breast-cancer gene signatures. J Massague, N Engl J Med 2007 356 3 294 297 10.1056/NEJMe068292 17229957
2. Gene-expression signatures in breast cancer. C Sotiriou L Pusztai, N Engl J Med 2009 360 8 790 800 10.1056/NEJMra0801289 19228622
3. Gene expression profiling predicts clinical outcome of breast cancer. LJ van't Veer H Dai MJ van de Vijver YD He AAM Hart M Mao HL Peterse K van der Kooy MJ Marton AT Witteveen, et al. Nature 2002 415 6871 530 11823860
4. A gene-expression signature as a predictor of survival in breast cancer. MJ van de Vijver YD He LJ van't Veer H Dai AAM Hart DW Voskuil GJ Schreiber JL Peterse C Roberts MJ Marton, et al. N Engl J Med 2002 347 25 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
5. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. S Paik S Shak G Tang C Kim J Baker M Cronin FL Baehner MG Walker D Watson T Park, et al. N Engl J Med 2004 351 27 2817 2826 10.1056/NEJMoa041588 15591335
6. Concordance among Gene-Expression-Based Predictors for Breast Cancer. C Fan DS Oh L Wessels B Weigelt DSA Nuyten AB Nobel LJ van't Veer CM Perou, N Engl J Med 2006 355 6 560 569 10.1056/NEJMoa052933 16899776
7. Comparison of prognostic gene expression signatures for breast cancer. B Haibe-Kains C Desmedt F Piette M Buyse F Cardoso L van't Veer M Piccart G Bontempi C Sotiriou, BMC Genomics 2008 9 1 394 10.1186/1471-2164-9-394 18717985
8. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. A Sweet-Cordero S Mukherjee A Subramanian H You J Roix C Ladd-Acosta J Mesirov T Golub T Jacks, Nat Genet 2005 37 48 55 15608639
9. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. DS Oh MA Troester J Usary Z Hu X He C Fan J Wu LA Carey CM Perou, J Clin Oncol 2006 24 11 1656 1664 10.1200/JCO.2005.03.2755 16505416
10. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. AH Bild G Yao JT Chang Q Wang A Potti D Chasse M-B Joshi D Harpole JM Lancaster A Berchuck, et al. Nature 2006 439 7074 353 10.1038/nature04296 16273092
11. Gene expression patterns associated with p53 status in breast cancer. M Troester J Herschkowitz D Oh X He K Hoadley C Barbier C Perou, BMC Cancer 2006 6 1 276 10.1186/1471-2407-6-276 17150101
12. Molecular definition of breast tumor heterogeneity. M Shipitsin L Campbell P Argani S Weremowicz N Bloushtain-Qimron J Yao T Nikolskaya T Serebryiskaya R Beroukhim M Hu, et al. Cancer Cell 2007 11 259 273 10.1016/j.ccr.2007.01.013 17349583
13. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. JI Herschkowitz K Simin VJ Weigman I Mikaelian J Usary Z Hu KE Rasmussen LP Jones S Assefnia S Chandrasekharan, et al. Genome Biol 2007 8 76 10.1186/gb-2007-8-5-r76 17493263
14. EGFR associated expression profiles vary with breast tumor subtype. K Hoadley V Weigman C Fan L Sawyer X He M Troester C Sartor T Rieger-House P Bernard L Carey, et al. BMC Genomics 2007 8 1 258 10.1186/1471-2164-8-258 17663798
15. The intestinal Wnt/TCF signature. L Van der Flier J Sabates-Bellver I Oving A Haegebarth M De Palo M Anti M Van Gijn S Suijkerbuijk M Van de Wetering G Marra, et al. Gastroenterology 2007 132 628 632 10.1053/j.gastro.2006.08.039 17320548
16. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. LH Saal P Johansson K Holm SK Gruvberger-Saal Q-B She M Maurer S Koujak AA Ferrando P Malmstrm L Memeo, et al. Proc Natl Acad Sci USA 2007 104 18 7564 7569 10.1073/pnas.0702507104 17452630
17. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. E Bosco Y Wang H Xu J Zilfou K Knudsen B Aronow S Lowe K ES, J Clin Invest 2007 117 218 228 10.1172/JCI28803 17160137
18. The functional loss of the retinoblastoma tumor suppressor is a common event in Basal-like and Luminal B breast carcinomas. J Herschkowitz X He C Fan C Perou, Breast Cancer Research 2008 10 75 (79 September) 10.1186/bcr2142 18782450
19. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. CJ Creighton A Casa Z Lazard S Huang A Tsimelzon SG Hilsenbeck CK Osborne AV Lee, J Clin Oncol 2008 26 25 4078 4085 10.1200/JCO.2007.13.4429 18757322
20. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. H Dai L van't Veer J Lamb YD He M Mao BM Fine R Bernards M van de Vijver P Deutsch A Sachs, et al. Cancer Res 2005 65 10 4059 4066 10.1158/0008-5472.CAN-04-3953 15899795
21. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. SL Carter AC Eklund IS Kohane LN Harris Z Szallasi, Nat Genet 2006 38 1043 1048 10.1038/ng1861 16921376
22. An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. T Hallstrom S Mori J Nevins, Cancer Cell 2008 13 1 2 10.1016/j.ccr.2007.11.031 18167332
23. Changes in differential gene expression because of warm ischemia time of radical prostatectomy specimens. A Dash IP Maine S Varambally R Shen AM Chinnaiyan MA Rubin, Am J Pathol 2002 161 5 1743 1748 12414521
24. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. J Chi Z Wang D Nuyten E Rodriguez M Schaner A Salim Y Wang G Kristensen A Helland A Børresen-Dale, et al. PLoS Med 2006 3 47 10.1371/journal.pmed.0030047 16417408
25. Relation of a Hypoxia Metagene Derived from Head and Neck Cancer to Prognosis of Multiple Cancers. SC Winter FM Buffa P Silva C Miller HR Valentine H Turley KA Shah GJ Cox RJ Corbridge JJ Homer, et al. Cancer Res 2007 67 7 3441 3449 10.1158/0008-5472.CAN-06-3322 17409455
26. A compact VEGF signature associated with distant metastases and poor outcomes. Z Hu C Fan C Livasy X He D Oh M Ewend LA Carey S Subramanian R West F Ikpatt, et al. BMC Med 2009 7 9 10.1186/1741-7015-7-9 19291283
27. Cell-type specific gene expression profiles of leukocytes in human peripheral blood. C Palmer M Diehn A Alizadeh B PO, BMC Genomics 2006 7 115 10.1186/1471-2164-7-115 16704732
28. LKB1 modulates lung cancer differentiation and metastasis. H Ji MR Ramsey DN Hayes C Fan K McNamara P Kozlowski C Torrice MC Wu T Shimamura SA Perera, et al. Nature 2007 448 7155 807 10.1038/nature06030 17676035
29. Module map of stem cell genes guides creation of epithelial cancer stem cells. D Wong H Liu T Ridky D Cassarino E Segal H Chang, Cell Stem Cell 2008 2 333 344 10.1016/j.stem.2008.02.009 18397753
30. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. I Ben-Porath M Thomson V Carey R Ge G Bell A Regev R Weinberg, Nat Genet 2008 40 499 507 10.1038/ng.127 18443585
31. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. AE Teschendorff A Miremadi S Pinder I Ellis C Caldas, Genome Biol 2007 8 157 10.1186/gb-2007-8-8-r157 17683518
32. High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. G Alexe GS Dalgin D Scanfeld P Tamayo JP Mesirov C DeLisi L Harris N Barnard M Martel AJ Levine, et al. Cancer Res 2007 67 22 10669 10676 10.1158/0008-5472.CAN-07-0539 18006808
33. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. HY Chang DSA Nuyten JB Sneddon T Hastie R Tibshirani T Srlie H Dai YD He LJ van't Veer H Bartelink, et al. Proc Natl Acad Sci USA 2005 102 10 3738 3743 10.1073/pnas.0409462102 15701700
34. Determination of stromal signatures in breast carcinoma. R West D Nuyten S Subramanian T Nielsen C Corless B Rubin K Montgomery S Zhu R Patel T Hernandez-Boussard, et al. PloS Biol 2005 3 187 10.1371/journal.pbio.0030187 15869330
35. The fibromatosis signature defines a robust stromal response in breast carcinoma. AH Beck I Espinosa CB Gilks M van de Rijn RB West, Lab Invest 2008 88 6 591 10.1038/labinvest.2008.31 18414401
36. Stromal gene expression predicts clinical outcome in breast cancer. G Finak N Bertos F Pepin S Sadekova M Souleimanova H Zhao H Chen G Omeroglu S Meterissian A Omeroglu, et al. Nat Med 2008 14 5 518 10.1038/nm1764 18438415
37. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. KR Hess K Anderson WF Symmans V Valero N Ibrahim JA Mejia D Booser RL Theriault AU Buzdar PJ Dempsey, et al. J Clin Oncol 2006 24 26 4236 4244 10.1200/JCO.2006.05.6861 16896004
38. A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling. PK Julka RT Chacko S Nag R Parshad A Nair DS Oh Z Hu CB Koppiker S Nair R Dawar, et al. Br J Cancer 2008 98 8 1327 10.1038/sj.bjc.6604322 18382427
39. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. F Huang K Reeves X Han C Fairchild S Platero TW Wong F Lee P Shaw E Clark, Cancer Res 2007 67 5 2226 2238 10.1158/0008-5472.CAN-06-3633 17332353 (Pubitemid 46424242)
40. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. CJ Creighton S Massarweh S Huang A Tsimelzon SG Hilsenbeck CK Osborne J Shou L Malorni R Schiff, Cancer Res 2008 68 18 7493 7501 10.1158/0008-5472.CAN-08-1404 18794137
41. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. P Wirapati C Sotiriou S Kunkel P Farmer S Pradervand B Haibe-Kains C Desmedt M Ignatiadis T Sengstag F Schutz, et al. Breast Cancer Research 2008 10 4 65 10.1186/bcr2124 18662380
42. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. C Desmedt B Haibe-Kains P Wirapati M Buyse D Larsimont G Bontempi M Delorenzi M Piccart S C, Clin Cancer Res 2008 14 5158 5165 10.1158/1078-0432.CCR-07-4756 18698033
43. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer. F Reyal M van Vliet N Armstrong H Horlings K de Visser M Kok A Teschendorff S Mook L van't Veer C Caldas, et al. Breast Cancer Research 2008 10 6 93 10.1186/bcr2192 19014521
44. Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. LJ Goldstein R Gray S Badve BH Childs C Yoshizawa S Rowley S Shak FL Baehner PM Ravdin NE Davidson, et al. J Clin Oncol 2008 26 25 4063 4071 10.1200/JCO.2007.14.4501 18678838
45. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. K Shedden JMG Taylor SA Enkemann M-S Tsao TJ Yeatman WL Gerald S Eschrich I Jurisica TJ Giordano DE Misek, et al. Nat Med 2008 14 8 822 10.1038/nm.1790 18641660
46. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Parker M Mullins M Cheang S Leung D Voduc T Vickery S Davies C Fauron X He Z Hu, et al. J Clin Oncol 2009 19204204
47. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Y Wang J Klijn Y Zhang A Sieuwerts M Look F Yang D Talantov M Timmermans M Meijer-van Gelder J Yu, et al. Lancet 2005 365 671 679 15721472
48. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. S Loi B Haibe-Kains C Desmedt P Wirapati F Lallemand A Tutt C Gillet P Ellis K Ryder J Reid, et al. BMC Genomics 2008 9 1 239 10.1186/1471-2164-9-239 18498629
49. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. AV Ivshina J George O Senko B Mow TC Putti J Smeds T Lindahl Y Pawitan P Hall H Nordgren, et al. Cancer Res 2006 66 21 10292 10301 10.1158/0008-5472.CAN-05-4414 17079448
50. The molecular portraits of breast tumors are conserved across microarray platforms. Z Hu F Cheng DS Oh JS Marron X He BF Qaqish C Livasy LA Carey E Reynolds L Dressler, et al. BMC Genomics 2006 7 96 10.1186/1471-2164-7-96 16643655
51. Adjustment of systematic microarray data biases. M Benito J Parker Q Du J Wu D Xiang CM Perou JS Marron, Bioinformatics 2004 20 1 105 114 10.1093/bioinformatics/btg385 14693816
52. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. LA Carey CM Perou CA Livasy LG Dressler D Cowan K Conway G Karaca MA Troester CK Tse S Edmiston, et al. JAMA 2006 295 2492 2502 10.1001/jama.295.21. 2492 16757721
53. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. V Popovici W Chen B Gallas C Hatzis W Shi F Samuelson Y Nikolsky M Tsyganova A Ishkin T Nikolskaya, et al. Breast Cancer Research 12 1 5 10.1186/bcr2468 20064235
54. Finding significant monochromatic sample-variable blocks in large datasets. A Shabalin V Weigman C Perou A Nobel, Bioinformatics 2009 19091771
55. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. BT Hennessy A-M Gonzalez-Angulo K Stemke-Hale MZ Gilcrease S Krishnamurthy J-S Lee J Fridlyand A Sahin R Agarwal C Joy, et al. Cancer Res 2009 69 10 4116 4124 10.1158/0008-5472.CAN-08-3441 19435916
56. A transcriptional response to Wnt protein in human embryonic carcinoma cells. J Willert M Epping J Pollack P Brown R Nusse, BMC Developmental Biology 2002 2 1 8 10.1186/1471-213X-2-8 12095419
57. A molecular signature of metastasis in primary solid tumors. S Ramaswamy K Ross E Lander T Golub, Nat Genet 2003 33 49 54 10.1038/ng1060 12469122
58. A multigenic program mediating breast cancer metastasis to bone. Y Kang P Siegel W Shu M Drobnjak S Kakonen C Cordán-Cardo T Guise M J, Cancer Cell 2003 3 537 549 10.1016/S1535-6108(03)00132-6 12842083
59. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. C Sotiriou S-Y Neo LM McShane EL Korn PM Long A Jazaeri P Martiat SB Fox AL Harris ET Liu, Proc Natl Acad Sci USA 2003 100 18 10393 10398 10.1073/pnas.1732912100 12917485
60. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. MPHM Jansen JA Foekens IL van Staveren MM Dirkzwager-Kiel K Ritstier MP Look ME Meijer-van Gelder AM Sieuwerts H Portengen LCJ Dorssers, et al. J Clin Oncol 2005 23 4 732 740 10.1200/JCO.2005.05.145 15681518
61. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. G Glinsky O Berezovska A Glinskii, J Clin Invest 2005 115 1503 1521 10.1172/JCI23412 15931389
62. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. C Sotiriou P Wirapati S Loi A Harris S Fox J Smeds H Nordgren P Farmer V Praz B Haibe-Kains, et al. J Natl Cancer Inst 2006 98 4 262 272 10.1093/jnci/djj052 16478745
63. Influence of Surgical Manipulation on Prostate Gene Expression: Implications for Molecular Correlates of Treatment Effects and Disease Prognosis. DW Lin IM Coleman S Hawley CY Huang R Dumpit D Gifford P Kezele H Hung BS Knudsen AR Kristal, et al. J Clin Oncol 2006 24 23 3763 3770 10.1200/JCO.2005.05.1458 16822846
64. Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer. M Buess D Nuyten T Hastie T Nielsen R Pesich P Brown, Genome Biology 2007 8 9 191 10.1186/gb-2007-8-9- r191 17868458
65. Transcriptional program induced by Wnt protein in human fibroblasts suggests mechanisms for cell cooperativity in defining tissue microenvironments. Z Klapholz-Brown GG Walmsley YM Nusse R Nusse PO Brown, PLoS ONE 2007 2 9 945 10.1371/journal.pone.0000945 17895986
66. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. A Bergamaschi E Tagliabue T Sørlie B Naume T Triulzi R Orlandi H Russnes J Nesland R Tammi P Auvinen, et al. The Journal of Pathology 2008 214 3 357 367 10.1002/path.2278 18044827
67. Genes that mediate breast cancer metastasis to lung. A Minn G Gupta P Siegel P Bos W Shu D Giri A Viale A Oshen W Gerald J Massague, Nature 2005 436 518 524 10.1038/nature03799 16049480
68. The prognostic role of a gene signature from tumorigenic breast-cancer cells. R Liu X Wang GY Chen P Dalerba A Gurney T Hoey G Sherlock J Lewicki K Shedden MF Clarke, N Engl J Med 2007 356 3 217 226 10.1056/NEJMoa063994 17229949
69. The lasso method for variable selection in the Cox model. R Tibshirani, Stat Med 1997 16 385 395 10.1002/(SICI)1097-0258(19970228)16:4<385::AID- SIM380>3.0.CO;2-3 9044528
70. Regression modelling strategies for improved prognostic prediction. F Harrell K Lee R Califf D Pryor R Rosati, Stat Med 1984 3 143 152 10.1002/sim.4780030207 6463451
71. Common markers of proliferation. ML Whitfield LK George GD Grant CM Perou, Nat Rev Cancer 2006 6 2 99 10.1038/nrc1802 16491069
72. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. L Perreard C Fan J Quackenbush M Mullins N Gauthier E Nelson M Mone H Hansen S Buys K Rasmussen, et al. Breast Cancer Research 2006 8 2 23 10.1186/bcr1399 16626501
73. The humoral immune system has a key prognostic impact in node-negative breast cancer. M Schmidt D Bohm C von Torne E Steiner A Puhl H Pilch H-A Lehr JG Hengstler H Kolbl M Gehrmann, Cancer Res 2008 68 13 5405 5413 10.1158/0008-5472.CAN-07-5206 18593943
74. T-cell metagene predicts a favourable prognosis in estrogen receptor negative and HER2 positive breast cancers. A Rody U Holtrich L Pusztai C Liedtke R Gaetje E Ruckhaeberle C Solbach L Hanker A Ahr D Metzler, et al. Breast Cancer Res 2009 11 15 10.1186/bcr2234 19272155
75. High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2-Positive, Node-Negative Tumors 1 cm or Smaller. AM Gonzalez-Angulo JK Litton KR Broglio F Meric-Bernstam R Rakkhit F Cardoso F Peintinger EO Hanrahan A Sahin M Guray, et al. J Clin Oncol 2009 27 34 5700 5706 10.1200/JCO.2009.23.2025 19884543